Table 1.
Patients characteristics and laboratory findings of 99 patients with COVID-19 pneumonia
| Total cohort (n = 100) | ICU COVID-19 patients (n = 52) | Non-ICU COVID-19 patients (n = 47) | |
|---|---|---|---|
| Median age (range) | 57 (18–91) | 55 (18–82) | 58 (18–91) |
| Male sex | 72 (73%) | 45 (87%) | 27 (57%) |
| Median WHO scale | 5 (3–8) | 7 (5–8) | 3 (3–8) |
| Comorbidities | |||
| No comorbidities as listed below | 16 (16.2%) | 5 (9.6%) | 11 (23.4%) |
| Obesity | 10 (10.1%) | 8 (15.4%) | 2 (4.3%) |
| Arterial Hypertension | 39 (29.4%) | 23 (44.2%) | 16 (34%) |
| Diabetes | 19 (19.2%) | 15 (28.8%) | 4 (8.5%) |
| Coronary heart disease | 17 (17.2%) | 7 (13.5%) | 10 (21.3%) |
| Congestive heart failure | 3 (3%) | 2 (3.8%) | 1 (2.1%) |
| COPD | 8 (8.1%) | 1 (2.1%) | 8 (8.1%) |
| Asthma | 2 (2%) | 1 (1.9%) | 1 (2.1%) |
| Chronic kidney disease | 3 (3%) | 1 (2.1%) | 2 (3.8%) |
| Cancer | 8 (8.1%) | 5 (9.6%) | 3 (6.4%) |
| Immunodeficiency | 4 (4%) | 1 (1.9%) | 3 (6.4%) |
| Organ transplantation | 5 (5.1%) | 2 (3.8%) | 3 (6.4%) |
| Chronic liver disease | 4 (4%) | 2 (3.8%) | 2 (4.3%) |
| Antifungal therapy | 12 (12%) | 12 (23.1%) | 0 (0%) |
| Antiviral therapy | 32 (32%) | 24 (46.2%) | 8 (17%) |
| Antibiotic therapy | 68 (68.7%) | 49 (94%) | 19 (40.4%) |
| Median interval between symptoms and hospital admission (days) | 7 (6–9) | 7.5 (7–13.3) | 7 (5–7) |
| Secondary bacterial infection | 32 (32.3%) | 29 (55.8%) | 3 (6.4%) |
| Nosocomial/community acquired infection | 84.3%/ 15.7% | 82.8%/ 17.2% | 100%/0% |
| Laboratory findings | |||
| PCT (ng/mL) on admission | 0.2 (0.1–0.4) | 0.35 (0.2–0.9) | 0.1 (0.1–0.1) |
| Highest PCT (ng/mL) | 0.3 (0.1–2.4) | 1.75 (0.1–80) | 0.1 (0.1–0.2) |
| Day of highest PCT after dmission | 1 (1–3) | 3 (1–7.5) | 1 (1–2) |
| CRP (mg/L) on admission | 84.4 (42.7–147.2) | 122 (77.5–185,1) | 52.4 (16.8–93.5) |
| Highest CRP (mg/L) | 135 (73.8–220) | 193.5 (133.3–332.8) | 73.8 (26–126) |
| Day of highest CRP after admission | 2 (1–5) | 3 (2–9) | 1 (1–3) |
| Deceased during hospital stay | 19 (19.2%) | 15 (28.8%) | 4 (8.5%) |
Data are presented as absolute numbers and relative frequencies (n(%)) or as median (IQR)
COVID-19 coronavirus disease 2019; ICU intensive care unit; WHO World health organisation; COPD chronic obstructive pulmonary disease; CRP C-reactive protein; PCT procalcitonin